Survey - Gem/Doce Poll
Researchers from the University Hospital Basel, Switzerland have developed an international survey on the use of Gemcitabine/Docetaxel in NMIBC and UTUC.
The survey will explore Gem/Doce use in non-muscle invasive bladder cancer and upper tract urothelial carcinoma. USANZ Members are invited to participate
The aim of the survey is to gain a more detailed global overview of the current use of Gem/Doce. The researchers would like to understand in which situations Gem/Doce is being used (e.g., BCG shortage, BCG-refractory disease, etc.) and how exactly it is being administered (dosage, timing, schedule).
The researchers are particularly interested in potential intercontinental differences in practice patterns.
Participation in this survey is voluntary and is estiminated to take five minutes of your time.
Download the survey participation flyer.